Dupilumab effective for atopic dermatitis in young children with, without comorbidities

The safety of this treatment was consistent with the biologic’s known safety profile as well, Mark Boguniewicz, allergist-immunologist, National Jewish Health [and professor of pediatrics, CU School of Medicine], and colleagues wrote.